Lucentis news from FiercePharma
NewsFDA: Don't blame us for Avastin change
Remember last year when Genentech said it wouldn't sell its cancer med Avastin to compounding pharmacies, which repackage it for off-label use in patients with macular degeneration -- and then blamed Read more...
Avastin-Lucentis trial may reshape pharma
We thought the head-to-head trial of Avastin and Lucentis for age-related macular degeneration was a big deal for Genentech, which Read more...
ALSO NOTED: Senate postpones hearings on Lucentis;Antibiotics overused in dementia patients;
> Lawmakers investigating Genentech's pricing of macular degeneration drug Lucentis have backed off of holding hearings on the issue. Read more...
NIH launches Avastin-Lucentis trial
Gentlemen (and ladies), start your eye injections. In other Avastin news, the big trial pitting the cancer drug against Genentech sister med Lucentis is now underway. Sponsored by the National Read more...
Canada to decide Lucentis' fate
The Lucentis versus Avastin match has moved to Canada. Officials there are arguing Read more...
Eye docs confront Genentech exec
Put a Genentech executive and a bunch of angry ophthalmologists in the same room, and what do you get? Fireworks. At a conference over the weekend, the company's president of product development, Read more...
| Press ReleasesPRESS RELEASE: Genentech President Defends Company’s Decision to Embargo Avastin Sales to Compounding Pharmacies Genentech President Defends Company’s Decision to Embargo Avastin Sales to Compounding Pharmacies Susan Desmond-Hellmann, MD, MPH, president of product development for Genentech, said she came to Read more... |
Get more Lucentis coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends